ArticleIntestinal Failure (New York, N.Y.)
Economic impact of intestinal failure from a patient perspective - A pilot study.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intestinal Failure (IF) is a complex and life-long illness, requiring home parenteral and/or enteral nutrition, multiple medications, dietary changes and input from multiple healthcare specialists. The aim of this pilot study is to quantify the economic impact of IF from the patient perspective. Materials and methods: A tailored questionnaire was developed, piloted and administered to adult IF patients within a quaternary hospital in Sydney, Australia. The questionnaire collected health-related out-of-pocket expenses (OOPE) over the past 12-months. Data was analysed using descriptive statistics (median and range). Results: A total of 13 participants responded to the questionnaire. OOPE in a 12-month period was AUD $6099 (AUD $3170 - $45,744); this was 24.4 % of annual reported income. OOPE for participants in metropolitan regions were higher than those living in regional or rural regions (AUD $6538 versus AUD $6099, respectively). Participants with a motility disorder spent more on total OOPE than those without a motility disorder (AUD $7178 versus AUD $3905); with the majority of people living in metropolitan regions. OOPE for medications was the highest individual cost per year, AUD $2160 (AUD $820 - $6000). Average potential lost income was AUD $62,310 per annum. Conclusion: This pilot study shows the significant economic burden for people living with IF, including loss of income. Results warrant expansion to assess burden over a larger patient group. IF services need to be aware of the financial burden experienced by this patient group and ensure they are supported to access financial aid where eligible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.